Manmeet Kaur, MD
Endocrinology, Diabetes & Metabolism · New Britain, CTNPI 1053555334
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $28,300 of the $43,666 with a category attached, or 64.8%. Lilly USA, LLC accounts for 87.9% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $27,424 and has fallen 95.5% since, to $1,229 in 2025. Among endocrinology, diabetes & metabolism clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 255 payments — averaging $171.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$38K
- Novo Nordisk$1K
- Valeritas, Inc.$758
- Dexcom, Inc.$543
- Abbott$518
- Amgen$375
- plus $2K from 22 others
What the payments were for
- Consulting fees$2,6006%
- Speaking & faculty fees$28,30065%
- Travel & lodging$6,98016%
- Food & beverage$5,70313%
- Education$830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 100 | $38,375 |
| Novo Nordisk | 65 | $1,237 |
| Valeritas, Inc. | 2 | $758 |
| Dexcom, Inc. | 20 | $543 |
| Abbott | 17 | $518 |
| Amgen | 5 | $375 |
| Amryt Pharma Holdings Ltd | 2 | $222 |
| Ascendis Pharma Endocrinology Inc | 4 | $190 |
| Tandem Diabetes Care, Inc. | 3 | $180 |
| AstraZeneca(2 entities) | 3 | $175 |
| Corcept Therapeutics | 3 | $175 |
| Xeris Pharmaceuticals, Inc. | 6 | $134 |
| Radius Health, Inc. | 1 | $106 |
| Insulet Corporation | 4 | $106 |
| AbbVie | 1 | $99 |
| Mannkind Corporation | 2 | $87 |
| Cequr Corporation | 3 | $74 |
| Neurocrine Biosciences, Inc. | 2 | $61 |
| Medtronic | 2 | $43 |
| Novartis | 2 | $36 |
| Embecta Corp. | 1 | $29 |
| Bayer | 1 | $26 |
| Sequel Med Tech, LLC | 1 | $24 |
| Halozyme Inc | 1 | $24 |
| Almatica Pharma LLC | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Chiesi USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,666 in reported general payments places this provider in the 90th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 216 | $289,899 |
| JardianceEmpagliflozin | 121 | $200,282 |
| MounjaroTirzepatide | 124 | $156,309 |
| TrulicityDulaglutide | 88 | $128,701 |
| FarxigaDapagliflozin Propanediol | 42 | $53,363 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $47,588 |
| Tresiba Flextouch U-100Insulin Degludec | 56 | $41,220 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $36,783 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $29,258 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 14 | $16,318 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $14,631 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $14,626 |
| Testosterone | 38 | $14,518 |
| SynthroidLevothyroxine Sodium | 124 | $13,883 |
| Novolog FlexpenInsulin Aspart | 42 | $12,569 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,237 | $295,551231 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $38,375 | $290,581236 claims |
| AstraZenecaFarxiga | $175 | $53,36342 claims |
| AbbVieSynthroid | $99 | $13,883124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
Other endocrinology, diabetes & metabolism in New Britain
- Joseph RosenblattNew Britain$235K
- Ela BanerjeeNew Britain$8K
- Egils BogdanovicsTorrington$608K
- Ania JastreboffNew Haven$536K
- Robert ObersteinHartford$516K
- Fadi Al-KhayerStorrs$489K
- Silvio InzucchiNew Haven$461K
- Philip GoldbergNew Haven$324K
- Kevan HeroldNew Haven$261K
- David DomenichiniBloomfield$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.